NKTR Nektar Therapeutics

Price (delayed)

$18.97

Market cap

$3.46B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.39

Enterprise value

$3.46B

Sector: Healthcare
Industry: Biotechnology

Highlights

The debt has shrunk by 64% YoY
Nektar Therapeutics's EPS has increased by 8% YoY and by 4% QoQ
Nektar Therapeutics's quick ratio has soared by 135% YoY but it has decreased by 9% from the previous quarter
Nektar Therapeutics's equity has decreased by 23% YoY and by 8% QoQ
The gross profit has declined by 22% since the previous quarter and by 11% year-on-year

Key stats

What are the main financial stats of NKTR
Market
Shares outstanding
182.31M
Market cap
$3.46B
Enterprise value
$3.46B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.48
Price to sales (P/S)
27.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.45
Earnings
Revenue
$125.99M
EBIT
-$427.72M
EBITDA
-$414.5M
Free cash flow
-$321.53M
Per share
EPS
-$2.39
Free cash flow per share
-$1.77
Book value per share
$5.46
Revenue per share
$0.69
TBVPS
$7.61
Balance sheet
Total assets
$1.46B
Total liabilities
$462.06M
Debt
$150.32M
Equity
$994.51M
Working capital
$975.42M
Liquidity
Debt to equity
0.15
Current ratio
8.89
Quick ratio
8.63
Net debt/EBITDA
0
Margins
EBITDA margin
-329%
Gross margin
83%
Net margin
-340.3%
Operating margin
-318.2%
Efficiency
Return on assets
-28.1%
Return on equity
-38.1%
Return on invested capital
-31.4%
Return on capital employed
-32.1%
Return on sales
-339.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NKTR stock price

How has the Nektar Therapeutics stock price performed over time
Intraday
0.58%
1 week
-5.62%
1 month
-0.89%
1 year
-11.15%
YTD
11.59%
QTD
-5.15%

Financial performance

How have Nektar Therapeutics's revenue and profit performed over time
Revenue
$125.99M
Gross profit
$104.57M
Operating income
-$400.87M
Net income
-$428.76M
Gross margin
83%
Net margin
-340.3%
The gross profit has declined by 22% since the previous quarter and by 11% year-on-year
The revenue has contracted by 18% from the previous quarter and by 8% YoY
The net margin has decreased by 17% QoQ
The operating margin has contracted by 14% from the previous quarter but it has grown by 3.8% YoY

Growth

What is Nektar Therapeutics's growth rate over time

Valuation

What is Nektar Therapeutics stock price valuation
P/E
N/A
P/B
3.48
P/S
27.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.45
Nektar Therapeutics's EPS has increased by 8% YoY and by 4% QoQ
The P/B is 96% below the 5-year quarterly average of 82.4 but 11% above the last 4 quarters average of 3.1
Nektar Therapeutics's equity has decreased by 23% YoY and by 8% QoQ
The stock's P/S is 25% more than its 5-year quarterly average of 21.7 and 18% more than its last 4 quarters average of 23.1
The revenue has contracted by 18% from the previous quarter and by 8% YoY

Efficiency

How efficient is Nektar Therapeutics business performance
The return on invested capital has declined by 41% year-on-year and by 4.3% since the previous quarter
NKTR's ROA is down by 23% YoY and by 3.3% from the previous quarter
Nektar Therapeutics's return on sales has decreased by 19% QoQ and by 6% YoY
Nektar Therapeutics's ROE has decreased by 19% YoY and by 3% from the previous quarter

Dividends

What is NKTR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NKTR.

Financial health

How did Nektar Therapeutics financials performed over time
The company's current ratio has surged by 135% YoY but it fell by 10% QoQ
Nektar Therapeutics's quick ratio has soared by 135% YoY but it has decreased by 9% from the previous quarter
The debt is 85% lower than the equity
The debt has shrunk by 64% YoY
The debt to equity has shrunk by 53% YoY but it rose by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.